Extracellular Vesicles Reflect the Efficacy of Wheatgrass Juice Supplement in Colon Cancer Patients During Adjuvant Chemotherapy.
adjuvant chemotherapy
colon cancer
cytokines
extracellular vesicles
thrombogenicity
wheatgrass juice
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
01
2020
accepted:
28
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
29
9
2020
Statut:
epublish
Résumé
Colorectal cancer (CC) is the third most common type of cancer, accounting for 10% of all cancer cases. Adjuvant chemotherapy is recommended in stages II-III CC. Wheatgrass juice (WGJ) from wheat seeds has high nutritional values, may induce synergistic benefits to chemotherapy and may attenuate chemotherapy-related side effects. Extracellular vesicles (EVs) are subcellular membrane blebs. EVs include exosomes (generated in the endosome, in size <150 nm) and microvesicles (shed from the plasma cell membrane) provide information on their parental cells and play a role in intercellular communication. We aimed to elucidate the effects of chemotherapy administration with supportive treatment of WGJ on CC patients' EVs characteristics. EVs were isolated from the blood samples of 15 healthy controls (HCs) and 50 CC patients post-surgery, treated by chemotherapy, with or without additional daily WGJ. Blood samples were taken before, during, and at the end of chemotherapy. EVs were characterized by size, concentration, membrane antigens and cytokine content using nanoparticle-tracking analysis, western blot, flow cytometry, and protein array methods. EVs were found to be similar by size and concentration with reduced levels of exosome markers (CD81) on samples at the end of combined treatment (chemotherapy and WGJ). Higher levels of endothelial EVs, which may indicate impairment of the vascular endothelial cells during treatment, were found in CC patients treated by chemotherapy only compared to those with chemotherapy and daily WGJ. Also, EVs thrombogenicity was lower in patients added WGJ compared to patients who had only chemotherapy (levels of tissue factor Daily consumption of WGJ during chemotherapy may reduce vascular damage and chemotherapy-related thrombogenicity, growth factors and cytokines, as reflected by the characteristics of patient's EVs.
Identifiants
pubmed: 32984039
doi: 10.3389/fonc.2020.01659
pmc: PMC7479215
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1659Informations de copyright
Copyright © 2020 Avisar, Cohen, Brenner, Bronshtein, Machluf, Bar-Sela and Aharon.
Références
J Thromb Haemost. 2017 Nov;15(11):2208-2217
pubmed: 28834179
J Extracell Vesicles. 2013 Feb 15;2:
pubmed: 24009893
Mini Rev Med Chem. 2015;15(12):1002-10
pubmed: 26156538
Oncotarget. 2017 Oct 12;8(58):99136-99149
pubmed: 29228759
Curr Cancer Drug Targets. 2011 May;11(4):451-64
pubmed: 21247378
Immunol Lett. 2017 Apr;184:7-14
pubmed: 28223102
Thromb Haemost. 2018 Mar;118(3):480-489
pubmed: 29490409
Proteomics. 2011 Jul;11(13):2745-51
pubmed: 21630462
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
Semin Immunol. 2014 Feb;26(1):75-9
pubmed: 24447345
Nat Cell Biol. 2008 May;10(5):619-24
pubmed: 18425114
J Altern Complement Med. 2007 Oct;13(8):789-91
pubmed: 17983333
Biochim Biophys Acta. 2014 Nov;1839(11):1256-72
pubmed: 25218966
J Thromb Haemost. 2017 May;15(5):848-857
pubmed: 28222250
J Exp Clin Cancer Res. 2015 May 13;34:42
pubmed: 25967108
Clin Cancer Res. 2003 Oct 15;9(13):4852-9
pubmed: 14581357
Scand J Gastroenterol. 2002 Apr;37(4):444-9
pubmed: 11989836
Blood. 2013 Sep 12;122(11):1873-80
pubmed: 23798713
BMC Genomics. 2009 Nov 25;10:556
pubmed: 19930720
Cytokine Growth Factor Rev. 2011 Aug;22(4):189-95
pubmed: 22019906
Blood Rev. 2007 May;21(3):157-71
pubmed: 17118501
J Transl Med. 2016 Feb 02;14:36
pubmed: 26838097
J Extracell Vesicles. 2013 Jun 18;2:
pubmed: 24009892
Mol Neurobiol. 2020 Oct;57(10):4156-4169
pubmed: 32676990
Thromb Res. 2012 Sep;130(3):479-84
pubmed: 22534418
J Oncol Pharm Pract. 2012 Sep;18(3):355-9
pubmed: 22333669
J Proteome Res. 2007 Dec;6(12):4646-55
pubmed: 17956143
J Clin Invest. 1997 Jul 15;100(2):411-8
pubmed: 9218519
Cancer Res. 2012 Mar 1;72(5):1092-102
pubmed: 22282655
Br J Cancer. 2003 Aug 4;89(3):465-9
pubmed: 12888813
Anticancer Res. 2015 Sep;35(9):4935-41
pubmed: 26254391
Nat Rev Immunol. 2002 Jul;2(7):527-35
pubmed: 12094227
Int J Mol Sci. 2019 Dec 31;21(1):
pubmed: 31906247
Oncotarget. 2017 Jun 28;8(38):63265-63280
pubmed: 28968987
J Cell Sci. 2010 May 15;123(Pt 10):1603-11
pubmed: 20445011
J Cell Physiol. 2015 Aug;230(8):1883-94
pubmed: 25546229
Nutr Cancer. 2007;58(1):43-8
pubmed: 17571966
Gut. 2001 Sep;49(3):409-17
pubmed: 11511564
Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):27-33
pubmed: 21160065
Nutrients. 2018 Oct 19;10(10):
pubmed: 30347664
J Exp Clin Cancer Res. 2016 Mar 25;35:54
pubmed: 27015840
World J Gastroenterol. 2015 Mar 7;21(9):2645-50
pubmed: 25759532
Ann Oncol. 2018 May 1;29(5):1099-1107
pubmed: 29438451
Carcinogenesis. 2001 Oct;22(10):1649-52
pubmed: 11577004
Cancer Chemother Pharmacol. 2012 Jan;69(1):57-64
pubmed: 21603868